Stock of cancer lab takes a hit

FORT MYERS — A possible change in future government reimbursements for cancer tests caused NeoGenomics shares to fall 14% on Wednesday.

The shares recovered some ground today, but investors worried about a recent announcement by Medicare that it will not pay as much for some cancer tests as it has previously. The company's shares are publicly traded on the Nasdaq (symbol: NEO; recent price: $3.27).

The announcement overshadowed an otherwise positive earnings report from Fort Myers-based NeoGenomics. The company reported it earned $857,000 on revenues of $18.3 million in the quarter ending Dec. 31. That compared with a loss of $113,000 on revenues of $14.9 million in the same quarter in 2012.